Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zschäbitz, Stefanie, Vallet, Sonia, Hadaschik, Boris, Debatin, Daniel, Fuxius, Stefan, Karcher, Andreas, Pahernik, Sascha, Spath, Cathleen, Duensing, Stefan, Jäger, Dirk, Hohenfellner, Markus, Grüllich, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370494/
https://www.ncbi.nlm.nih.gov/pubmed/28367230
http://dx.doi.org/10.7150/jca.17644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370494/
https://www.ncbi.nlm.nih.gov/pubmed/28367230
http://dx.doi.org/10.7150/jca.17644

Ejemplares similares